SAN JOSE, Calif.--(BUSINESS WIRE)--DFINE®, Inc., a market leader in the treatment of spinal diseases, today announced data from the American Society of Clinical Oncology 50th Annual Meeting in Chicago highlighting the benefits of Targeted Radiofrequency Ablation™ (t-RFA) therapy with the STAR™ Tumor Ablation System.
Help employers find you! Check out all the jobs and post your resume.
